Ribba2012 - Low-grade gliomas, tumour growth inhibition model

View the 2014-03 Model of the Month entry for this model
Model Identifier
BIOMD0000000521
Short description
Ribba2012 - Low-grade gliomas, tumour growth inhibition model

Using longitudinal mean tumour diameter (MTD) data, this model describe the size evolution of low-grade glioma (LGG) in patients treated with chemotherapy or radiotherapy.

This model is described in the article:

Ribba B, Kaloshi G, Peyre M, Ricard D, Calvez V, Tod M, Cajavec-Bernard B, Idbaih A, Psimaras D, Dainese L, Pallud J, Cartalat-Carel S, Delattre JY, Honnorat J, Grenier E, Ducray F.
Clin. Cancer Res. 2012 Sep; 18(18): 5071-5080

Abstract:

PURPOSE: To develop a tumor growth inhibition model for adult diffuse low-grade gliomas (LGG) able to describe tumor size evolution in patients treated with chemotherapy or radiotherapy.

EXPERIMENTAL DESIGN: Using longitudinal mean tumor diameter (MTD) data from 21 patients treated with first-line procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea, and vincristine (PCV) chemotherapy, we formulated a model consisting of a system of differential equations, incorporating tumor-specific and treatment-related parameters that reflect the response of proliferative and quiescent tumor tissue to treatment. The model was then applied to the analysis of longitudinal tumor size data in 24 patients treated with first-line temozolomide (TMZ) chemotherapy and in 25 patients treated with first-line radiotherapy.

RESULTS: The model successfully described the MTD dynamics of LGG before, during, and after PCV chemotherapy. Using the same model structure, we were also able to successfully describe the MTD dynamics in LGG patients treated with TMZ chemotherapy or radiotherapy. Tumor-specific parameters were found to be consistent across the three treatment modalities. The model is robust to sensitivity analysis, and preliminary results suggest that it can predict treatment response on the basis of pretreatment tumor size data.

CONCLUSIONS: Using MTD data, we propose a tumor growth inhibition model able to describe LGG tumor size evolution in patients treated with chemotherapy or radiotherapy. In the future, this model might be used to predict treatment efficacy in LGG patients and could constitute a rational tool to conceive more effective chemotherapy schedules.

To the extent possible under law, all copyright and related or neighbouring rights to this encoded model have been dedicated to the public domain worldwide. Please refer to CC0 Public Domain Dedication for more information.

Format
SBML (L2V4)
Related Publication
  • A tumor growth inhibition model for low-grade glioma treated with chemotherapy or radiotherapy.
  • Benjamin Ribba, Gentian Kaloshi, Mathieu Peyre, Damien Ricard, Vincent Calvez, Vincent Calvez, Michel Tod, Branka Cajavec-Bernard, Ahmed Idbaih, Dimitri Psimaras, Linda Dainese, Johan Pallud, Stéphanie Cartalat-Carel, Jean-Yves Delattre, Jérôme Honnorat, Emmanuel Grenier, François Ducray
  • Clinical cancer research : an official journal of the American Association for Cancer Research , 9/ 2012 , Volume 18 , Issue 18 , pages: 5071-5080 , PubMed ID: 22761472
Contributors
Submitter of the first revision: Vijayalakshmi Chelliah
Submitter of this revision: Lucian Smith
Curator: Lucian Smith
Modeller: Vijayalakshmi Chelliah

Metadata information

is (2 statements)
BioModels Database BIOMD0000000521
BioModels Database MODEL1402250000

isDescribedBy (1 statement)
PubMed 22761472

hasTaxon (1 statement)
Taxonomy Homo sapiens

isVersionOf (2 statements)
Human Disease Ontology benign glioma
Gene Ontology defense response to tumor cell

hasProperty (1 statement)
Mathematical Modelling Ontology Ordinary differential equation model


Curation status
Curated


Connected external resources